Mayo Clinic | Strategic Alliance Partners

November 04, 2024

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.

October 17, 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

October 17, 2024

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

October 07, 2024

Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.

October 04, 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

October 03, 2024

Mayo Clinic will enhance and expand access to cancer care and clinical trials for patients and communities, thanks to a philanthropic commitment.

September 30, 2024

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.

September 25, 2024

Treatment for blood cancers is advancing, giving more options to people living with the disease.

September 18, 2024

Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.

September 13, 2024

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

September 10, 2024

About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.

September 10, 2024

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

September 09, 2024

Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.

September 09, 2024

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

September 05, 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

September 04, 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

August 29, 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

August 29, 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

August 22, 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

August 22, 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.